Fuji Pharma Co.,Ltd. Logo

Fuji Pharma Co.,Ltd.

Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.

4554 | T

Overview

Corporate Details

ISIN(s):
JP3816200004
LEI:
Country:
Japan
Address:
千代田区三番町5番地7
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Fuji Pharma Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products for medical use. The company specializes in hormone medicines, particularly for obstetrics and gynecology, and injectable drugs. Its portfolio also includes internal drugs, external use medications, and diagnostic products. In addition to its proprietary products, Fuji Pharma offers a wide range of contract manufacturing services for various formulations, including solids, injections, ointments, creams, and liquids. The company is noted for its extensive experience and specialized quality containment technology in the production of hormone-based pharmaceuticals.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-05-09 04:10
Registration Form
確認書
Japanese 8.7 KB
2025-05-09 04:09
Interim Report
半期報告書-第61期(2024/10/01-2025/09/30)
Japanese 216.6 KB
2024-12-23 04:46
Post-Annual General Meeting Information
臨時報告書
Japanese 25.0 KB
2024-12-23 04:37
Registration Form
確認書
Japanese 8.7 KB
2024-12-23 04:33
Governance Information
内部統制報告書-第60期(2023/10/01-2024/09/30)
Japanese 23.3 KB
2024-12-23 04:32
Registration Form
有価証券報告書-第60期(2023/10/01-2024/09/30)
Japanese 1.7 MB
2024-07-18 09:11
Registration Form
有価証券届出書(参照方式)
Japanese 285.7 KB
2024-05-10 07:27
Quarterly Report
四半期報告書-第60期第2四半期(2024/01/01-2024/03/31)
Japanese 216.0 KB
2024-05-10 07:27
Report Publication Announcement
確認書
Japanese 8.6 KB
2024-02-09 08:20
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-02-09 08:19
Quarterly Report
四半期報告書-第60期第1四半期(2023/10/01-2023/12/31)
Japanese 178.7 KB
2023-12-21 07:28
Post-Annual General Meeting Information
臨時報告書
Japanese 27.9 KB
2023-12-21 07:26
Registration Form
確認書
Japanese 8.7 KB
2023-12-21 07:25
Governance Information
内部統制報告書-第59期(2022/10/01-2023/09/30)
Japanese 23.3 KB
2023-12-21 07:23
Annual Report
有価証券報告書-第59期(2022/10/01-2023/09/30)
Japanese 1.6 MB

Automate Your Workflow. Get a real-time feed of all Fuji Pharma Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Fuji Pharma Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Fuji Pharma Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

REGENXBIO Inc. Logo
Developing AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.
United States of America
RGNX
Rein Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel therapies for orphan pulmonary diseases and fibrosis.
United States of America
RNTX
Rekah Pharmaceutical Prod Ltd. Logo
A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.
Israel
REKA
Relay Therapeutics, Inc. Logo
Developing precision medicines for oncology & genetic diseases by analyzing protein motion.
United States of America
RLAY
Repare Therapeutics Inc. Logo
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia
REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden
RESP
REVELATION BIOSCIENCES, INC. Logo
Develops therapies that reprogram the innate immune system to reduce inflammation-related damage.
United States of America
REVB
REVIVA PHARMACEUTICALS HOLDINGS, INC. Logo
Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.
United States of America
RVPH
Revolution Medicines, Inc. Logo
A clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
United States of America
RVMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.